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Abstract
Introduction: Status epilepticus (SE) is a life-threatening condition requiring prompt treatment in the emergency department to control
seizures and limit potential neurologic damage. Fosphenytoin is a water-soluble prodrug of phenytoin (an established treatment option for
SE) that has been developed to overcome the often severe venous adverse events that can occur following the intravenous administration
of phenytoin.
Aims: The objective of this article is to review the evidence for the use of fosphenytoin in the treatment of SE.
Evidence review: Fosphenytoin can be infused more rapidly than phenytoin and there is evidence that therapeutic drug levels are achieved
at least at a similar rate. Although few studies have been conducted in SE patients, there is evidence that fosphenytoin is at least as effective
as phenytoin in terms of response and control of SE. There is also moderate evidence that there are fewer vascular adverse events following
intravenous fosphenytoin compared with phenytoin administration when both drugs are infused at the recommended dosage and rate.
Evidence from pharmacoeconomic studies indicates that a reduction in the incidence of adverse events and their subsequent management
are critical factors for cost-effectiveness with fosphenytoin.
Clinical value: In conclusion, fosphenytoin is a valuable treatment option for the rapid treatment of SE; the risk of venous adverse events
is lower than with phenytoin when administered at the recommended rate. 
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Outcome measure Evidence Implications
Patient-oriented evidence
Reduction in adverse events Moderate Has advantages with improved tolerability compared with intravenous
phenytoin. Faster rate of administration with fosphenytoin compared with phenytoin.
Improved tolerability contributes to cost-effectiveness
More rapid discharge from emergency department Limited  Further studies required
Use in children and elderly, and other patient groups
with poor peripheral vascular access
Limited  Further studies required
More rapid achievement of therapeutic blood levels Moderate More rapid infusion rate 
Seizure control  Moderate Effective treatment but more rapid control of status epilepticus seizures with
fosphenytoin has not been demonstrated 
Economic evidence
Cost-effectiveness Moderate Cost-effectiveness reliant upon reduced incidence of adverse events
Disease-oriented evidence
Core evidence clinical impact summary for fosphenytoin in status epilepticusScope, aims, and objectives
Status epilepticus (SE) is a serious, life-threatening condition that
is often presented at casualty or emergency departments (ED).
Phenytoin, a commonly used drug for the treatment of SE, is
associated with poor solubility that complicates the use of the
intravenous formulation. To overcome this limitation
fosphenytoin, a water-soluble prodrug of phenytoin, was
introduced in 1996. 
The objective of this review is to evaluate the evidence for the use
of fosphenytoin in the treatment of SE. 
Methods
The English language medical literature was reviewed for
appropriate articles relating to fosphenytoin for the treatment of SE.
The following databases were searched on January 5, 2005 using
the search terms ‘fosphenytoin; status epilepticus AND guidelines’
for articles published between January 1990 and December 2004
(inclusive):
• PubMed, www.ncbi.nlm.nih.gov/entrez
• Database of Abstracts of Reviews of Effectiveness (DARE), NHS
Economic Evaluations Database (NHSEED), Health Technology
Assessment (HTA), www.york.ac.uk/inst/crd/darehp.htm
• NHS HTA, www.ncchta.org
• National Guidelines Clearinghouse, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• Cochrane Database of Systematic Reviews, www.cochrane.org
• Clinical Evidence, www.clinicalevidence.com
A total of 186 articles were identified and animal or in vitro studies
were excluded.
Table 1 summarizes the levels of evidence of articles identified from
the search strategy (see Editorial Information on inside back cover).
No systematic reviews were identified for the use of fosphenytoin in
the treatment of SE, four papers were of level 2 evidence and there
were eight papers and abstracts of level ≥3 evidence (including
case studies). In addition, four articles relating to
pharmacoeconomic outcomes with fosphenytoin were identified.
Six additional articles were identified from a hand search of SE
publications to ensure that relevant studies were not overlooked.
Disease overview
Epilepsy, the presence of unprovoked recurrent seizures, is a
serious disorder that affects many patients worldwide. For
example, in the USA alone it has a prevalence of approximately 6.6
per 1000, with about 2.5 million people affected by the condition.
Up to 28% of patients with epilepsy require treatment in EDs
annually (ACEP 2004). The economic burden of epilepsy is
substantial with annual direct costs of treatment per patient
reported to be $US329–2642 and $US1531–5065 in the USA and
Italy, respectively (Jobst & Holmes 2004). In addition, the condition
also imposes a costly societal burden on individuals, families, and
dependents. The medical management of epilepsy is
predominantly with the long-term use of oral antiepileptic drugs.
However, parenterally administered drugs are necessary for the
management of some conditions and emergency situations. 
One such epileptic condition is SE, which is a serious medical
emergency familiar to EDs, acute medical wards, and intensive care
units. Although there is no universally accepted definition of this
life-threatening condition it has been defined in a number of
incidence studies as ‘a clinical seizure lasting more than 30 min, or
repeated seizures over a period of more than 30 min without
intervening recovery of consciousness’ (Rosenow et al. 2002).
Based on earlier animal studies, it has been postulated that the
brain can compensate for the increased demands of SE for only
30 min and that the outcomes for patients (e.g. mortality) with a
seizure duration less than 30 min are significantly better (P<0.001)
compared with those over 30 min (DeLorenzo et al. 1999). 
In general, SE can be further classified, based on clinical and
electrographic criteria, into generalized convulsive status
epilepticus (GCSE) and nonconvulsive status epilepticus (NCSE).
GCSE is the most common and easily recognized form of SE and
is usually diagnosed by observation alone. It is characterized by
unconsciousness, tonic-clonic muscle activity, urinary
incontinence, and tongue biting. However, with prolonged seizure
activity, these clinical characteristics become less apparent. The
fundamental pathophysiology of SE involves a failure of inherent
cellular mechanisms to prevent sustained seizure activity (Scott et
al. 1998). The failure may be due to either ineffective inhibitory or
excessive excitatory processes, although it is likely that several
factors are involved in this poorly understood process (Lowenstein
& Alldredge 1998).
NCSE may account for 30–40% of all cases of SE, an incidence of
approximately five to nine per 100 000 in the general population. It
is characterized by continuous or near continuous focalized or
generalized seizure activity detected by electroencephalogram
(EEG) for at least 30 min without physical convulsions. NCSE carries
an increased risk for evolving into refractory SE and is associated
with a three-fold increase in long-term mortality compared with the
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Table 1 | Evidence base included in the review
Category Number of records
Initial search 186 0
records excluded 165 0
records included 21 0
Additional studies identified 3 3
Level 1 clinical evidence 0 0
Level 2 clinical evidence 4 0
Level ≥3 clinical evidence 2 3
trials other than RCT 0 0
case studies 3 0
Economic evidence 4 0
RCT, randomized controlled trial.
Full papers Abstractshealthy population. The overall mortality in SE has been reported to
be approximately 30% (estimates range from 2 to 61%), whereas
NCSE-associated mortality appears to be higher, approximately
50% (estimates range from 33 to 57%) (Rüeegg & Dichter 2003).
There are about 102 000–152 000 new cases of SE in the USA per
year and around 22 000–42 000 deaths annually associated with the
condition (DeLorenzo et al. 1995). At approximately 22%, this
mortality rate is within the overall SE mortality range reported by
Rüeegg and Dichter (2003). Data from other countries also show that
SE is common. For example, the minimum estimated incidence is
approximately 20 per 100 000 in Switzerland and Germany
(Rosenow et al. 2002), while in India, SE accounted for 11% of
neurologic admissions to intensive care units (Swaminathan et al.
1998). It is interesting to note that in studies in the USA, the incidence
of SE in the black population is three times higher than in Caucasians
(reviewed in Rosenow et al. 2002). In addition, the incidence is higher
in males and is age-related, with the highest incidence in children and
the elderly. As the relative proportion of the aging population is
increasing globally, it is expected that there will be a corresponding
increase in the incidence of SE (Rosenow et al. 2002). About a third
of all instances of SE occur in patients with a history of epilepsy or
febrile seizures, one-third in patients whose first sign of epilepsy is an
episode of SE, and the remaining third result from encephalopathic
insult to the brain (Treiman 1999). Other causes of SE include trauma,
hypoxia, stroke, infection, and drug withdrawal (Table 2).
Patients with a first episode of SE are at considerable risk for both
future episodes and the development of chronic epilepsy (Lowenstein
& Alldredge 1998). Although outcome is usually worse in patients with
SE of long duration and those with physiologic disturbances, it is the
etiology of SE (Table 2) that has the greatest influence on outcome.
Mortality is highest in elderly patients or when SE is secondary to an
acute event (e.g. acute stroke, central nervous system infection, head
trauma, metabolic disturbances, drug toxicity, and hypoxia). In
contrast, SE secondary to previous strokes, withdrawal from alcohol
or anticonvulsant drugs, tumours, or epilepsy has a more favorable
prognosis (Manno 2003). To date, one study has looked at a long-term
outcome, 10-year mortality after a first episode of SE that received
medical attention (Logroscino et al. 2002). In this study 40% of
patients who survived the first 30 days after an incident episode of SE
died within the next 10 years: three times the mortality rate compared
with the general population over the same time period. This study
indicated that significant risk factors for long-term mortality
(prolonged SE duration, myoclonic SE, and advanced age) replicated
those factors that influence short-term mortality (Towne et al. 1994).
Recently, the inpatient costs associated with SE in the USA alone
have been estimated to range from $US3.8–7 billion per year
(Sirven & Waterhouse 2003).
Current therapy options for status epilepticus
Because of the emergency nature of the condition, the aim of SE
treatment is the prompt termination of seizure activity and
subsequent prevention of seizure recurrence. Once the patient is
diagnosed with SE, rapid administration of drug therapy is
necessary to both reduce the potential for neurologic morbidity and
increase the probability of response to therapy; SE of long duration
is less responsive to drug therapy compared with SE of shorter
duration (Lowenstein & Alldredge 1998). 
Initial drug treatment of SE usually involves a parenterally
administered benzodiazepine (lorazepam or diazepam) or a
hydantoin (Lowenstein & Alldredge 1998; Holmes & Riviello 1999;
Manno 2003). Most cases of SE respond to these initial treatment
options. However, SE that does not respond to these therapies is
considered to be refractory. Agents used in this situation include
phenobarbital or pentobarbital, propofol, and midazolam. Current
treatments for SE are shown in Table 3. 
There have been a number of attempts to identify optimal treatment
regimens for SE. Treatment protocols shorten the time needed to
control seizures. Typically they include the sequential
administration of benzodiazepines, phenytoin, and phenobarbital,
and finally pentobarbital-induced coma for patients with refractory
seizures (Manno 2003). However, it has been suggested that actual
drug choice may be less important than the development of a
protocol itself (Shorvon 2001), but this reflects the importance of
achieving a rapid response. 
The ideal drug for the treatment of SE should be easy to administer,
achieve immediate and long-lasting antiseizure activity, and also be
free from serious respiratory depression, cardiovascular and
sedative effects, and local irritation at the injection site. However, all
the currently available therapies used to treat SE fail this ideal in
some respect. Adverse events with the benzodiazepines include
respiratory suppression, hypotension, and sedation. Similarly,
although the hydantoins lack sedative effects they have also been
associated with hypotension. In addition, local venous irritation,
pain, and phlebitis can also occur with intravenous phenytoin.
Phenobarbital, which is sedative, is often used following failure to
control SE with a benzodiazepine or hydantoin; however, it too is
associated with systemic hypotension. Finally, propofol, another
option if previous therapy has failed, may lead to instances of
severe metabolic acidosis particularly in children with metabolic
enzymatic defects (Manno 2003). Despite the potential adverse
events associated with these agents, they still have a place in the
therapeutic management of SE. 
Even with the development of medication protocols, treatment may
still vary among physicians. A recent survey of neurologists (mainly
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Subtherapeutic antiepileptic drug levels
Cerebral trauma
Infection, central nervous system or general
Cerebrovascular accident
Metabolic disturbance (e.g. electrolyte imbalance)
Drug overdose
Hypoxia
History of epilepsy
Tumor
Alcohol abuse
Table 2 | Etiologic factors of generalized convulsive status
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in medical schools and private practice) evaluated current
treatment preferences for GCSE. Of the 106 respondents 76%
initially treated patients with intravenous lorazepam, while 95%
would use phenytoin or fosphenytoin if seizures continued for
10 min following initial benzodiazepine treatment (Claassen et al.
2003). Fosphenytoin was more popular with respondents than
phenytoin (65 versus 31%, respectively). Phenytoin and
fosphenytoin have also been recommended for second-line
treatment in general guidelines for treating GCSE (Lowenstein &
Alldredge 1998; Appleton et al. 2000; Rosenow et al. 2002). 
Phenytoin can be used as an initial treatment for cessation of
seizure activity, for maintaining a prolonged antiseizure effect
following effective treatment with a benzodiazepine, or when
benzodiazepines are ineffective. Its mode of action is to limit the
repetitive firing of action potentials by slowing the rate of recovery
of voltage-activated sodium channels. Parenteral sodium phenytoin
is formulated with 40% propylene glycol and 10% ethanol in water
for injection adjusted to pH 12 with sodium hydroxide. The
recommended starting dose for intravenous phenytoin is 20 mg/kg
(via a large vein) given at a maximal rate of 50 mg/min to achieve
therapeutic serum concentrations of 10–20 mg/L. Therefore it
would take nearly 30 min to give the required dose to a patient
weighing 70 kg, which is undesirable given that the aim of SE
treatment is the prompt termination of seizure activity. The
recommended dose for children is 18 mg/kg infused over 20 min
(maximum infusion rate 1 mg/kg per min), which is similarly
inappropriate (Appleton et al. 2000). In addition, adverse effects
following use of intravenous phenytoin in SE can be common and
are cardiovascular-related: hypotension, QT prolongation, and
cardiac dysrhythmias may occur and these are direct effects of the
active ingredient and excipients, plus local venous irritation and
pain may occur. Propylene glycol in the formulation contributes to
the hypotension and cardiac arrhythmias observed with the rapid
infusion of phenytoin (Fischer et al. 2003). 
One of the most poorly understood and potentially serious local
complications of intravenous phenytoin administration is the purple
glove syndrome, which is characterized by progressive limb edema,
discoloration, and pain. In the only reported systematic study of this
syndrome, the incidence of purple glove syndrome was 5.9% (nine
of 152) in patients receiving intravenous phenytoin (O’Brien et al.
1998). Thus, while the efficacy of phenytoin for the treatment of
acute seizures and SE is well established (Treiman et al. 1998), its
Drug (route) Potential AEs  Advantages Disadvantages
Benzodiazepines 
Diazepam
(iv, rectal)
Respiratory depression, hypotension,
decreased level of consciousness
Most rapidly acting (10–20 s)
Stable in liquid form at room temperature
Rectal administration commonly used for
children
Short duration of action (<20 min)
Second-line drug required
Lorazepam
(iv)
Respiratory depression, hypotension,
decreased level of consciousness
Long duration of action (4–6 h)
May be least respiratory depressant in class
Refrigerated storage
Delay in brain uptake (2 min to maximal
effect)
Midazolam
(iv, im)
Respiratory depression, hypotension,
decreased level of consciousness
Rapid acting (<1 min) Short duration of action
Second-line drug required
Minimal CV effects
Hydantoins
Fosphenytoin
(iv)
Hypotension, cardiac arrhythmias, pruritus Potentially fewer AEs
Faster infusion rate than phenytoin
CV monitoring
AEs
High acquisition cost
Phenytoin (iv) Hypotension, QT interval prolongation,
PGS, venous irritation, phlebitis
Low cost
Effective in longer-term seizure recurrence 
AE profile (infusion rate, CV monitoring)
Barbiturates
Phenobarbital (iv) Hypotension, respiratory depression,
decreased level of consciousness
Long acting Long half-life
More hypoventilation, more hypotension
than benzodiazepines or phenytoin
Pentobarbital (iv) Hypotension, respiratory depression,
decreased level of consciousness
Shorter half-life than phenobarbital More hypoventilation, more hypotension
than benzodiazepines or phenytoin
General anesthetic
Propofol (iv) Hypotension, respiratory depression,
acidosis, lipemia
Rapid onset of action
Rapid recovery
AE profile in children 
AE, adverse event; CV, cardiovascular; im, intramuscular; iv, intravenous; PGS, purple glove syndrome.
Table 3 | Summary of antiepileptic drugs used for the treatment of status epilepticus (adapted from Manno 2003; Sirven &
Waterhouse 2003)
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parenteral formulation, specifically excipients and high alkalinity,
limits its rate of administration and influences its tolerability.
Fosphenytoin is a water-soluble prodrug of phenytoin and is
converted to the active compound by nonspecific phosphatases in
the blood (reviewed in Browne 1997). The dose of fosphenytoin is
expressed as phenytoin equivalence (75 mg fosphenytoin is labelled
as 50 mg phenytoin equivalent). Unlike phenytoin, fosphenytoin is
not formulated with propylene glycol and its pH of 8.6–9 means that
it may be infused more rapidly, up to 150 mg phenytoin equivalent
per minute. Thus, a starting dose of 20 mg/kg intravenous phenytoin
equivalent may be given to a 70-kg patient in just under 10 min.
Potential practical benefits with fosphenytoin include more rapid
achievement of therapeutic blood levels and decreased risk and
incidence of serious adverse effects compared with phenytoin. In
addition, fosphenytoin may be preferable for patients with difficult
vascular access (e.g. children, the elderly, and intravenous drug
abusers). Although intramuscular administration of fosphenytoin
may be used as a loading dose strategy, this route is not
recommended for treating SE because of the delay in achieving
therapeutic plasma concentrations of phenytoin (Fierro et al. 1996). 
Clinical evidence for the role of fosphenytoin in
the treatment of SE
Short-term outcomes are commonly examined in SE clinical trials.
This is due to their importance in the longer-term prognosis
following an episode of SE and treatment with antiepileptic drugs.
Examples of short-term outcomes include achievement of
therapeutic drug levels, time to seizure recurrence, failure of first-
line therapy, and time to discharge from the ED. There are few
studies of patients with new-onset seizures in the ED and most
reports use abnormal laboratory or diagnostic tests (e.g. EEG) as
the outcome measure (ACEP 2004). 
The long-term prognosis for SE is improved if seizures are controlled
within 30 min of onset. Thus, rapid drug control of seizures is an
advantage and a component of this is the timely achievement of
therapeutic drug levels. Fosphenytoin should have an advantage
over phenytoin in this respect, as it can be infused more rapidly.
Clinical evidence is available that compares the achievement of
therapeutic drug levels, seizure control, and tolerability (particularly
vascular reactions) with fosphenytoin and phenytoin. 
Achievement of therapeutic drug levels
There is some good evidence supporting the achievement of
therapeutic levels of phenytoin with intravenous fosphenytoin
(Table 4). Most studies evaluating the pharmacokinetics of
fosphenytoin and phenytoin use ‘achievement of a therapeutic
serum concentration of phenytoin’ as the primary outcome
measure. However, ‘therapeutic’ phenytoin serum level may be a
misleading term, as some patients can be seizure-free at
phenytoin levels <10 mg/L and yet others require serum levels
>20 mg/L for seizure control (ACEP 2004). Studies evaluated here
have included both SE and non-SE patient populations, as the
achievement of therapeutic drug levels is independent of the
presence of SE. 
In a study in children with malaria and SE (in endemic tropical
regions falciparum malaria is a common cause of convulsions in
children), maximum peak plasma phenytoin concentrations were
achieved more rapidly with intravenous fosphenytoin compared
with intravenous phenytoin (0.08 vs 0.37 h) (Ogutu et al. 2003).
Two abstracts have reported the achievement of therapeutic levels
of phenytoin with fosphenytoin administration in single-arm, open-
label studies in patients with SE. Total phenytoin concentrations of
≥10 mg/L and free phenytoin concentrations of ≥1 mg/L were
achieved within 10–20 min of commencing the infusion of
fosphenytoin in 40 patients with SE; mean infusion duration 11 min
(Allen et al. 1995). In another study of 39 patients (22 with SE and
17 non-SE patients), treated with intravenous fosphenytoin
(10–20 mg/kg phenytoin equivalent), pharmacokinetic data were
collected from 20 patients (Runge et al. 1995). Therapeutic levels of
free phenytoin (0.9–1.8 mg/mL [sic]) were achieved within 10 min in
all 20 patients. However, it should be noted that the target infusion
rate for fosphenytoin was 50–100 mg/min for non-SE patients and
100–150 mg/min for SE patients and it is unclear what proportion
of participants from these two groups provided the
pharmacokinetic data. 
Although the maximal rate of intravenous administration is three
times faster with fosphenytoin than with phenytoin, there is only
limited evidence that phenytoin levels are actually achieved faster
with fosphenytoin. For example, in a small, randomized controlled
study, phenytoin (n=14) and fosphenytoin (n=15) were administered
Level of
evidence
Outcomes Comparators Study population  Study
reference
2 Mean times to achieve therapeutic drug concentrations were
0.24 h (iv PT) and 0.21 h (iv FOS). Both iv groups were
significantly shorter compared with oral PT (5.62 h, P<0.001)
FOS (iv) vs. PT
(iv or oral)
n=45 patients with subtherapeutic PT levels
within 48 h of a seizure (oral PT n=16; iv PT
n=14; iv FOS n=15)
Swadron et al.
2004
3 Mean time to peak PT concentrations following loading dose
were 0.08 h (iv FOS), 0.37 h (iv PT), and 0.38 h (im FOS)
FOS (iv or im)
vs PT (iv)
n=38 children with SE and severe falciparum
malaria (iv PT n=11; iv FOS n=16; im FOS n=11) 
Ogutu et al.
2003
3 Total and free phenytoin concentrations of ≥10 mg/L and ≥1mg/L
respectively, achieved within 10–20 min of starting infusion
FOS (iv) n=40 patients with SE  Allen et al.
1995
3 Therapeutic PT levels achieved within 10 min of FOS infusion
of all (n=20) patients with PK data
FOS (iv) n=39 patients following benzodiazepine therapy  Runge et al.
1995
FOS, fosphenytoin; im, intramuscular; iv, intravenous; PK, pharmacokinetic; PT, phenytoin.
Table 4 | Summary of outcome evidence for intravenous fosphenytoin: achievement of therapeutic drug levels
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at the recommended initial rates of 50 and 150 mg/min,
respectively, and therapeutic phenytoin concentrations were
reached at a mean of 0.24 and 0.21 h, respectively (Swadron et al.
2004). One possible reason for the difference is the delay (half-life
8–15 min) in the conversion of fosphenytoin to phenytoin by
phosphatases in blood and other tissues (Browne 1997). Plasma
phenytoin concentrations were measured using an immunoassay in
this study (Swadron et al. 2004). This method may overestimate
actual phenytoin plasma concentrations by 1.2–6-fold when
fosphenytoin is present (Fischer et al. 2003). The other studies used
more specific high-performance liquid chromatography assays
where interference does not occur (Fischer et al. 2003).
Seizure control in SE patients
The evidence suggests that fosphenytoin is as effective as
phenytoin in speed of seizure resolution and in the proportion of
patients responding to treatment (Table 5).
When considering the use of intravenous fosphenytoin specifically
for the treatment of SE four studies categorized at level 3 evidence
or higher were identified. Two of these were single-arm design
(Allen et al. 1995; Runge et al. 1995), while the third was a study in
children with SE plus the added complication of falciparum malaria
(Ogutu et al. 2003). Finally, although the fourth study involved a
large number of patients only nine were diagnosed with SE (Coplin
et al. 2002).
In the study in children with malaria plus SE, the defined clinical
outcomes were abolition of seizures within 30 min of commencing
drug therapy, or SE characterized by recurrent convulsions of short
duration, which were considered controlled if there were no
convulsions within 12 h of drug therapy (Ogutu et al. 2003). SE was
controlled in seven of 16 children following intravenous
fosphenytoin and in four of 11 following intravenous phenytoin. 
In an abstract of a single-arm, open-label study in SE patients,
seizure control was achieved in 85% (37 of 40) patients within 30 min
of receiving intravenous fosphenytoin (mean infusion duration 11 min)
(Allen et al. 1995). In the second single-arm study 39 patients (SE
n=22, epilepsy patients n=17) were treated with intravenous
fosphenytoin. No seizures were noted in 38 (97%) of these patients
after intravenous fosphenytoin. The mean dose in SE patients was
16.1 mg/kg (range 9.6–22 mg/kg) administered at a mean infusion
rate of 134.4 mg/min (range 54–183 mg/min) (Runge et al. 1995). 
In a large, open-label randomized study, 256 ED patients were
prescribed 279 parenteral doses of phenytoin or fosphenytoin
(phenytoin n=77, fosphenytoin n=202). Time to seizure cessation in
the nine patients diagnosed with SE was not significantly different
with fosphenytoin compared with phenytoin (Coplin et al. 2002)
Tolerability and adverse events
There is some good evidence supporting the improved tolerability of
fosphenytoin compared with phenytoin (Table 6). Some studies with
non-SE patient populations have been used in this evaluation, as
tolerability of fosphenytoin does not depend on the presence of SE. 
In a study of 29 non-SE patients, phenytoin and fosphenytoin were
administered intravenously at the recommended initial rates of
50 and 150 mg/min, respectively, and a total of 27 and 32 adverse
events were recorded in the respective groups (P=0.55). However,
pain and phlebitis were experienced more frequently following
phenytoin compared with fosphenytoin (11 vs 3, P<0.001). The
occurrence of perineal pruritus was exclusively associated with
fosphenytoin (12 vs 0, P<0.0001), requiring a reduction in infusion
rate in some patients (Swadron et al. 2004). Perineal pruritus is
reversible and has previously been noted to occur with high
infusion rates of fosphenytoin (Sirven & Waterhouse 2003). 
There is further evidence to support improved tolerability with
fosphenytoin. In a randomized, double-blind, crossover study,
12 healthy volunteers received a 30-min infusion of 250 mg
phenytoin, or fosphenytoin equivalent, to evaluate venous irritation.
Phenytoin was associated with a significantly higher level of
infusion site pain (all subjects, P<0.05) and phlebitis (eight subjects
P<0.05); cording occurred in six subjects. Erythema and
tenderness were prominent at the conclusion of the phenytoin
infusion and again on examination 24 h later. In contrast,
fosphenytoin was associated with mild pain in only two subjects,
and phlebitis in one; no instances of erythema or cording were
noted (Jamerson et al. 1994). In this early study, both drugs were
infused at the same rate; however, it is now recognized that
fosphenytoin may be administered at three times the rate of
phenytoin. 
Venous-related adverse events were also noted more often with
intravenous loading doses of phenytoin compared with
fosphenytoin in a randomized, double-blind study in 23 non-SE
Level of
evidence
Outcomes Comparators Study population  Study
reference
2 For nine patients with SE, seizures ceased after 31.8 min
with PT vs 49.5 min with FOS (P=0.8)
FOS (iv or im)
vs PT (iv)
n=9 with SE from 256 patients Coplin et al.
2002
3 SE terminated within 30 min of FOS infusion in 85% of patients  FOS (iv) n=40 patients with SE Allen et al.
1995
3 Seizures controlled in 97% of patients FOS (iv) n=39 patients following benzodiazepine therapy  Runge et al.
1995
3 SE controlled in 36% (iv PT), 44% (iv FOS), and 64%
(im FOS) of patients
FOS (iv or im)
vs PT (iv)
n=38 children with SE and severe falciparum
malaria (iv PT n=11; iv FOS n=16; im FOS n=11) 
Ogutu et al.
2003
FOS, fosphenytoin; im, intramuscular; iv, intravenous; PT, phenytoin; SE, status epilepticus.
Table 5 | Summary of outcome evidence for intravenous fosphenytoin: seizure control in status epilepticus patients
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patients (Andrews et al. 1994). Pain and phlebitis occurred in 83%
of phenytoin recipients compared with none in those treated with
fosphenytoin. Infusion rate adjustment, as a result of adverse
events, was required in significantly more phenytoin recipients
compared with those receiving fosphenytoin (67 vs 12%; P<0.05).
Although there were complaints of transient, generalized itching and
warmth in 53% of the fosphenytoin group, as noted above, infusion
rate adjustment was only necessary in a minority of the group. 
In another double-blind, randomized study, 88 patients received
intravenous fosphenytoin and 28 patients received intravenous
phenytoin to achieve serum phenytoin concentrations of
10–20 mg/L. This was followed by maintenance doses for up to 14
days. The frequency of mild irritation was significantly lower
following fosphenytoin compared with phenytoin (6 vs 25%,
P<0.05) and reductions in infusion rates were required in 17 and
36% of recipients, respectively (Boucher et al. 1996). 
Infusion site changes were also highlighted in a review of 208
patients (with epilepsy, neurosurgical or with SE) participating in
three studies. A larger proportion of fosphenytoin recipients
maintained their original intravenous site (58 vs 38%), and change
in infusion site was less common with fosphenytoin compared with
phenytoin (11 vs 42%) (Baron et al. 1995). 
A questionnaire was used to capture effectiveness data from 33
nurses in critical care, emergency, and neurology services in a
metropolitan area in the USA. In this study, venous irritation
occurred in a mean of 62.3±43.4% of patients receiving phenytoin
loading doses and 74±32.9% receiving maintenance doses. Each
local reaction required 34.7±9.3 min of nursing time for
management. In contrast, adverse events associated with
fosphenytoin were uncommon (0.3±1%) and there were no nurse-
reported local reactions following intravenous (or intramuscular)
administration (Armstrong et al. 1999) (see also ‘Resource
utilization’ below).
One study, however, reported that fosphenytoin and phenytoin are
associated with a similar incidence of adverse events. In this large,
open-label randomized study of 256 ED patients who were
prescribed 279 parenteral doses of phenytoin or fosphenytoin
(phenytoin n=77, fosphenytoin n=202), the incidence of adverse
events was similar between the two treatment groups (odds ratio 0.7,
confidence interval 0.3–1.4; P=0.3). It is worth noting that, although
the time taken to administer fosphenytoin (13 min, range 1–75 min)
was significantly shorter than with phenytoin (45 min, range
15–165 min, P<0.001), the protocol specified the rate of phenytoin
administration as 20 mg/min (vs maximum recommended rate of
50 mg/min). Thus, the reduced rate of administration with phenytoin
is the most likely reason for the lower incidence of adverse events,
since it would avoid serious adverse events, including drug
extravasation and hypotension. In addition, fosphenytoin was also
administered at a reduced rate of 100 mg phenytoin equivalent per
minute (Coplin et al. 2002). Since only nine patients of the 256
patients had SE, rapid seizure resolution was not the prime objective
of the study. Hence, the low rates of infusion are not necessarily
appropriate for the treatment of SE.
Economic evidence
When compared strictly on acquisition cost, fosphenytoin is more
expensive than phenytoin. It has been reported that the difference in
cost with fosphenytoin is 10–20 times greater when compared with
generic versions of intravenous phenytoin (Jobst & Holmes 2004). To
get an overall evaluation of the economic impact of using
fosphenytoin to treat SE, the costs associated with adverse events,
rapid seizure control and discharge from ED, and long-term sequelae
need to be considered. However, at present there is no published
Table 6 | Summary of outcome evidence for intravenous fosphenytoin: adverse events
Level of
evidence
Outcomes Comparators Study population  Study
reference
2 Lower incidence of infusion site irritation with iv FOS (6%) compared
with iv PT (25%, P<0.05)
FOS (iv or im)
vs PT (iv)
n=116 neurosurgical patients (n=88 iv FOS;
n=28 iv PT)
Boucher et al.
1996
2 Total of 17 (oral PT), 27 (iv PT), and 32 (iv FOS) AEs
Significantly fewer AEs with oral PT vs both iv groups, P≤0.02
FOS (iv) vs PT
(iv or oral)
n=45 patients (oral PT n=16; iv PT n=14;
iv FOS n=15)
Swadron et al.
2004
2 Venous irritation (pain) reported by 12 subjects receiving PT vs two
subjects receiving FOS. Phlebitis, eight cases with PT vs one case
with FOS (P<0.05); and six cases of cording vs 0 instances with FOS
FOS (iv) vs PT
(iv)
n=12 healthy volunteers (crossover study) Jamerson et
al. 1994
2 Infusion rate altered because of an AE with 6.5% PT patients vs
6.4% FOS patients (P=1.0)
AE frequency 9.1% with PT vs 15.8% with FOS (P=0.3)
FOS (iv or im)
vs PT (iv)
n=256 ED patients (279 parenteral doses
of a PT equivalent; FOS n=202; PT n=77)
Coplin et al.
2002
3 AEs arising from loading doses included adjustment of infusion rate in
67% PT vs 12% FOS recipients (P<0.05). Injection site pain occurred
in 83% PT vs 0% FOS recipients 
FOS (iv) vs PT
(iv)
n=17 FOS, n=6 PT Andrews et al.
1994
3 Initial iv site maintained in a higher proportion of FOS recipients (58%)
vs PT recipients (38%)
Fewer site changes (due to irritation) with FOS (11%) vs PT (42%)
FOS (iv) vs PT
(iv)
n=208 (n=167 FOS; n=41 PT). Review of
3 studies
Baron et al.
1995
3 Nurse-reported venous irritation in 62.3–74% of PT recipients vs 0%
with FOS
FOS (iv or im)
vs PT (iv)
n=33 nurses from critical care, ED and
neurology services 
Armstrong et
al. 1999
AE, adverse event; ED, emergency department; FOS, fosphenytoin; im, intramuscular; iv, intravenous; PT, phenytoin; SE, status epilepticus.evidence specifically comparing fosphenytoin with phenytoin in
patients with SE so any extrapolation of results conducted in other
patient groups must therefore be treated with caution. 
Since fosphenytoin and phenytoin are bioequivalent and therefore
of equivalent efficacy, it is unlikely that there will be any difference
in patient outcome costs in terms of the proportion achieving
seizure reduction. Therefore, differences in drug-related patient
outcome costs of SE treatment are likely to include the failure of the
patient to respond to the treatment, the period spent in the ED (time
to discharge), and the management of drug-related adverse events.
As fosphenytoin can be administered more rapidly, and it is at least
as well tolerated as phenytoin, cost differences with these latter
outcomes may, in theory, favour fosphenytoin. 
Four pharmacoeconomic analyses comparing intravenous
fosphenytoin with intravenous phenytoin in the ED setting have
been conducted in the USA (Table 7). The study by Marchetti et al.
suggested a cost saving of $US386.89 with fosphenytoin relative to
phenytoin (Marchetti et al. 1996). However, this study used clinical
results from a multicenter trial conducted in one state and financial
data from a different institution in California, which would probably
differ with both other states and other countries. In addition,
calculation of the cost of emergency room treatment relied upon
average fixed and variable costs, whereas only variable or marginal
care costs are recommended for this type of analysis (Weinstein et
al. 1996). However, more pertinent to this review, patients with SE
were actually excluded from the analysis. 
In the analysis performed by Rudis et al. (2004), the most cost-
effective loading method in most settings was phenytoin
administered orally. The time taken to achieve therapeutic blood
levels with this route of administration precludes its use as a
treatment for SE. A more relevant comparison in this study showed
that the incremental cost-effectiveness ratio (i.e. the difference in
costs divided by the difference in health outcomes) was
$US387.27/h of ED time saved for intravenous fosphenytoin
versus intravenous phenytoin (Table 7) (Rudis et al. 2004). In this
study, drug administration was carried out at a General Clinical
Research Center under conditions which do not accurately
represent acute treatment. In addition, SE patients were excluded
(Swadron et al. 2004).
A study using cost-minimization analysis (i.e. the costs of two
methods producing the same outcome) by Touchette and Rhoney
(2000) showed that phenytoin was the preferred option in 97.3%
of occasions: expected total treatment costs $US5.39 vs 110.14
with fosphenytoin (Table 7). However, one-way sensitivity analysis
demonstrated that the frequency and cost of treating an episode
of purple glove syndrome could possibly affect the decision. A
two-way sensitivity analysis was conducted with the cost and
frequency of purple glove syndrome as variables. For fosphenytoin
to be the preferred option the rate of purple glove syndrome with
phenytoin had to exceed 1% and/or the cost of managing this
adverse event had to exceed $US10 000/episode (Touchette &
Rhoney 2000). The base case analysis was derived from a study
that used reduced rates of administration of phenytoin and
fosphenytoin, which biased the magnitude of the difference in
adverse events seen with the intravenous administration rates of
the two drugs (Coplin et al. 2002). The rate of purple glove
syndrome with phenytoin treatment in this study is therefore likely
to be lower than expected. O’Brien et al. reported an incidence of
purple glove syndrome with phenytoin of up to 5.9% (O’Brien et al.
1998). Thus it may be that fosphenytoin could be more cost-
effective when a higher incidence of adverse events, such as
purple glove syndrome, with phenytoin is taken into account. 
Level of
evidence
Analysis and outcome Comparators Study population Study
reference
2 Cost-minimization analysis from an RCT
Total treatment cost for base case of $US5.39 for PT vs. $US110.14
for FOS. PT was the preferred option for 97.3% of patients
FOS (iv) vs PT (iv) Base case from a randomized trial
(n=77 PT; n=202 FOS)
Touchette &
Rhoney 2000;
Coplin et al.
2002
2 Cost-effectiveness based on rates of AE and time to safe discharge from
ED from an RCT 
Treatment cost per patient was $US2.83, 21.16, and 175.19 for oral PT,
iv PT, and iv FOS, respectively 
Cost-effectiveness ratios were $US3.90/h of ED time saved for oral PT
vs iv PT and $US387.27/h of ED time saved for iv FOS vs iv PT
FOS (iv) vs PT (iv) Outcomes and costs from an RCT.
(n=16 oral PT; n=14 iv PT; n=15 iv
FOS)
Rudis et al.
2004;
Swadron et al.
2004
2 Drug acquisition cost and estimated cost to manage AEs within the ED 
Total ED drug-related AE costs per patient were $US536.86 for PT
compared with $US66.68 for FOS. Subtracting drug acquisition costs
results in a net saving of $US386.89 with FOS
FOS (iv) vs PT (iv) Not SE patients, n=39 FOS; n=13 PT Marchetti et
al. 1996
2 Cost estimation and cost-effectiveness 
For loading doses average cost-effectiveness ratio of iv PT alone
($US225) was higher than iv FOS ($US130)
Incremental cost-effectiveness ratio was $US97 to replace PT
loading doses with FOS
FOS (iv) vs PT (iv) Study based on questionnaire given to
nurses to determine incidence and
outcomes with AEs with PT and FOS
Armstrong et
al. 1999
AE, adverse effect; ED, emergency department; FOS, fosphenytoin; iv, intravenous; PT, phenytoin; RCT, randomized clinical trial.
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Finally, cost data were used with effectiveness data from a
questionnaire (covering drug administration, frequency of
adverse events and their management) used with 33 nurses to
determine cost-effectiveness with fosphenytoin (Armstrong et al.
1999). The study showed that the average expected cost of
phenytoin alone ($US58) was less than when 50% of patients
were treated with fosphenytoin and 50% with phenytoin ($US94),
or when fosphenytoin was used alone ($US130). However, the
cost-effectiveness ratio is a more useful measure, as it reflects
the cost to achieve the loading dose of the drug without
complication. Thus, the average cost-effectiveness ratios were
$US225 for phenytoin alone, $US149 for the 50 : 50 option and
$US130 for fosphenytoin alone. The incremental cost-
effectiveness ratio was approximately $US97 to replace
phenytoin loading doses with fosphenytoin, which was accepted
as a reasonable increase in cost to achieve a reduction in
adverse events (Armstrong et al. 1999).
Resource utilization
Rapid control of seizures in SE is necessary to limit the potentially
damaging neurologic morbidity and the resulting costs in treating
complications that can occur if treatment is delayed. The
advantages of fosphenytoin compared with phenytoin include a
faster rate of administration and a reduced potential for adverse
events, particularly venous irritation and cardiac toxicity.
Monitoring potential adverse events is essential when using
intravenous phenytoin, and typically blood pressure, respiration,
and continuous electrocardiogram (ECG) are observed. As the risk
of hypotension exists with intravenous fosphenytoin
administration at the recommended rate of administration
(≤150 mg phenytoin equivalent per minute) continuous monitoring
of these parameters is also essential. Therefore cost implications
associated with the use of monitoring equipment are present
irrespective of the choice between intravenous phenytoin or
fosphenytoin for treating SE. 
Since the infusion rate for fosphenytoin can be up to three times
faster than that with phenytoin this may save time in the ED and
reduce resource use. There is also a potential saving of resource
use through the avoidance of adverse events, and it has been
estimated that the use of intravenous fosphenytoin results in an
incremental cost-effectiveness of $US97 per adverse event
avoided (Armstrong et al. 1999). Although there has been a focus
on the large difference in cost between the two drugs this must be
weighed against the medical costs and resources necessary to
treat complications resulting from intravenous phenytoin or
sequelae of inadequately controlled prolonged SE.
Patient group/population 
Most patients with SE are eligible for treatment with intravenous
fosphenytoin. There is limited evidence that fosphenytoin may be
a more appropriate choice in selective populations. First, large vein
access for the administration of intravenous phenytoin can be
problematic in children, the elderly, or other SE patients with
restricted venous access. In addition, the formulation can be
painful and there is a risk of extravasation. Therefore, the use of
intravenous fosphenytoin via peripheral vein access may offer
advantages over phenytoin, although there is currently no
published evidence in these specific groups. Second, in resource-
poor countries fosphenytoin may offer both clinical and practical
advantages compared with intravenous phenytoin. For example,
intravenous phenytoin must be infused slowly when treating SE,
but this is not always possible in some basic health facilities
(Ogutu et al. 2003). Therefore, fosphenytoin may be a useful option
in these circumstances, although this must be weighed against the
impact of its higher acquisition cost in countries with limited
healthcare resources.
There is limited evidence from case studies (level 4 evidence)
indicating that parenteral fosphenytoin may be useful in seizure
management in premature or extremely low-birthweight infants
(Kriel & Cifuentes 2001). However, close monitoring of free
phenytoin levels is advised, as there may be some variability in
therapeutic phenytoin plasma concentrations. For example,
unexpected subtherapeutic levels of phenytoin following
intravenous fosphenytoin were observed in a 3-year-old boy (Koul
& Deleu 2002) and one infant aged ≤1 year (Takeoka et al. 1998).
The elimination half-life of intravenous fosphenytoin was not
significantly different between neonates (<29 days), infants (2 days
to <2 years), children (2 to <12 years), and adolescents (12 to <17
years). In addition, the elimination half-life in children (7.1 min; 5–10
years) is not significantly different to that in adults (7.9 min; 16–75
years) (Fischer et al. 2003). Therefore, as the rate of conversion of
fosphenytoin to phenytoin remains consistent with age it would
appear that the subtherapeutic levels of phenytoin seen in some
neonates and infants (Takeoka et al. 1998; Koul & Deleu 2002) may
be attributable to high clearance of phenytoin (reviewed in Fischer
et al. 2003). Thus, it may be prudent to monitor therapeutic blood
levels of phenytoin carefully following fosphenytoin administration
in these groups. 
Dosage, administration, and formulations
Fosphenytoin (5,5-diphenyl-3-[(phosphonooxy)methyl]-2,4-
imidazolidinedione disodium salt; Cerebyx®; fosphenytoin sodium
injection) is a prodrug of phenytoin and accordingly, its
anticonvulsant effects are attributable to phenytoin. It is supplied in
vials containing 75 mg/mL fosphenytoin sodium equivalent to
50 mg/mL phenytoin sodium after administration. This formulation
is supplied as a ready-mixed solution in water for injection and
Tromethamine (tris) buffer adjusted to pH 8.6–9 with either
hydrochloric acid or sodium hydroxide. 
The loading dose of fosphenytoin for treating SE is 15–20 mg
phenytoin equivalent per kilogram administered at 100–150 mg
phenytoin equivalent per minute. Fosphenytoin administered
intramuscularly should not be used in the treatment of SE
because therapeutic phenytoin concentrations may not be
reached as quickly as with intravenous administration. 
Fosphenytoin is indicated for short-term parenteral administration
when other means of phenytoin administration are unavailable,
inappropriate, or deemed less advantageous. The safety and
effectiveness of fosphenytoin in this use has not been
systematically evaluated for more than 5 days. Fosphenytoin can
be used for the control of GCSE and the prevention and treatment
of seizures occurring during neurosurgery. It can also be
substituted, short term, for oral phenytoin (Cerebyx 2002). 
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Clinical value
Fosphenytoin retains the pharmacologic properties of phenytoin with
the advantage of an improved adverse event profile. Two factors that
influence outcome following therapy for SE are good drug tolerability
and rapid administration, and the available evidence suggests that
fosphenytoin is superior to phenytoin in both instances. 
Evidence from available studies in SE patients shows that
fosphenytoin is at least as effective as phenytoin both in terms of
speed of seizure resolution and the number of patients that
respond in the treatment of the condition. 
There is moderate evidence that therapeutic phenytoin blood levels
after intravenous fosphenytoin administration are achieved at least
at a similar rate compared with intravenous phenytoin.
There is also evidence confirming that the risk of venous adverse
events with fosphenytoin is lower than with phenytoin, when
administered at the recommended rate. Blood pressure and
cardiac monitoring should be maintained with fosphenytoin,
particularly during and immediately after the infusion, because
hypotension and arrhythmias can occur with the active principle
(phenytoin). 
There are patient populations for whom treatment with phenytoin may
not be appropriate, in particular those with poor peripheral vascular
access (e.g. children, the elderly, and intravenous drug abusers).
Fosphenytoin may therefore be a preferred option in these patients
although there is very limited evidence to confirm this benefit. 
Clearly the higher acquisition cost of fosphenytoin compared with
phenytoin is an issue. Nevertheless, there is evidence that when
fosphenytoin is administered as recommended the incidence of
adverse events is lower than with phenytoin, thereby avoiding
costly management and treatment of these events, which would
influence the cost-effectiveness of fosphenytoin. 
Thus, current evidence suggests that fosphenytoin is a valuable
drug for the rapid treatment and control of SE.
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